These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 18025271)

  • 1. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
    Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
    Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
    Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
    Le XF; Pruefer F; Bast RC
    Cell Cycle; 2005 Jan; 4(1):87-95. PubMed ID: 15611642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of breast cancer cells to radiation by trastuzumab.
    Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z
    Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.
    García-Morales P; Hernando E; Carrasco-García E; Menéndez-Gutierrez MP; Saceda M; Martínez-Lacaci I
    Mol Cancer Ther; 2006 Sep; 5(9):2172-81. PubMed ID: 16985050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Fukazawa H; Noguchi K; Murakami Y; Uehara Y
    Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb.
    Good DW; George T; Watts BA
    J Biol Chem; 2008 Sep; 283(39):26602-11. PubMed ID: 18660503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative regulation by p70 S6 kinase of FGF-2-stimulated VEGF release through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts.
    Takai S; Tokuda H; Hanai Y; Harada A; Yasuda E; Matsushima-Nishiwaki R; Kato H; Ogura S; Ohta T; Kozawa O
    J Bone Miner Res; 2007 Mar; 22(3):337-46. PubMed ID: 17181399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
    Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
    Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.
    Yoon S; Lee MY; Park SW; Moon JS; Koh YK; Ahn YH; Park BW; Kim KS
    J Biol Chem; 2007 Sep; 282(36):26122-31. PubMed ID: 17631500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
    Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
    Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
    Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation.
    Wing LY; Chen HM; Chuang PC; Wu MH; Tsai SJ
    J Biol Chem; 2005 May; 280(20):19937-47. PubMed ID: 15760907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
    Miller TW; Forbes JT; Shah C; Wyatt SK; Manning HC; Olivares MG; Sanchez V; Dugger TC; de Matos Granja N; Narasanna A; Cook RS; Kennedy JP; Lindsley CW; Arteaga CL
    Clin Cancer Res; 2009 Dec; 15(23):7266-76. PubMed ID: 19934303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.